Clinical Criteria Updates Notification June 2021

September 28, 2021
group-label
Button Group
size
md
orientation
horizontal
alignment
center
button-type
lh-button
variant
text
text
Pharmacy
media-label
label
link
Pharmacy
icon-position
right
full-width
false
full-width-mobile
false
button-type
lh-button
variant
text
text
Medical Policy & Clinical Guidelines
media-label
label
link
Medical Policy & Clinical Guidelines
icon-position
right
full-width
false
full-width-mobile
false
button-type
lh-button
variant
text
text
Blue Medicare
media-label
label
link
Blue Medicare
icon-position
right
full-width
false
full-width-mobile
false

Please note, this communication applies to Healthy Blue + Medicare℠ (HMO D-SNP) offered by Blue Cross and Blue Shield of North Carolina.

Summary: On August 21, 2020, November 20, 2020, and June 24, 2021, the Pharmacy and Therapeutics (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Insert plan. These policies were developed, revised, or reviewed to support clinical coding edits.

Visit  Clinical Criteria  to search for specific policies. If you have questions or need additional information, use this email.

Please see the explanation/definition for each category of Clinical Criteria below:

  • New: newly published criteria
  • Revised: addition or removal of medical necessity requirements, new document number
  • Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive

Please share this notice with other members of your practice and office staff.

Please note: The  Clinical Criteria  listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.

lh-header-fill
true
lh-sticky-header-column
true
Effective date Document number Clinical Criteria title New or revised
December 20, 2021 *ING-CC-0201 Rybrevant (amivantamab-vmjm) New
December 20, 2021 *ING-CC-0042 Monoclonal Antibodies to Interleukin-17 Revised
December 20, 2021 *ING-CC-0050 Monoclonal Antibodies to Interleukin-23 Revised
December 20, 2021 ING-CC-0125 Opdivo (nivolumab) Revised
December 20, 2021 ING-CC-0124 Keytruda (pembrolizumab) Revised
December 20, 2021 *ING-CC-0102 GnRH Analogs for Oncologic Indications Revised
December 20, 2021 ING-CC-0076 Nulojix (belatacept) Revised
December 20, 2021 *ING-CC-0077 Palynziq (pegvaliase-pqpz) Revised
December 20, 2021 ING-CC-0067 Prostacyclin Infusion and Inhalation Therapy Revised
December 20, 2021 ING-CC-0194 Cabenuva (cabotegravir extended-release; rilpivirine extended-release) Injection Revised

For more information, visit Healthy Blue + Medicare

BNCCARE-0200-21 September 2021